Latest Genentech Inc. Stories

2006-08-28 08:20:23

CHICAGO (Reuters) - Biotechnology companies Genentech Inc. and Biogen Idec Inc. said on Monday cancer drug Rituxan was successful at treating multiple sclerosis in a midstage trial. Genentech and Biogen Idec said they will continue to analyze the study results and will submit the data for presentation at an upcoming medical meeting. "These initial results exceeded our expectations," said Hal Barron, Genentech senior vice president, development, and chief medical officer.

2006-06-30 19:20:42

By Lisa Richwine WASHINGTON (Reuters) - A Genentech Inc. drug that reversed vision loss in some patients won U.S. approval on Friday for treating the leading cause of blindness in the elderly. Injected into the eye monthly, the drug Lucentis maintained vision in 95 percent of patients with the wet form of age-related macular degeneration (AMD) who were treated for 12 months. Eyesight improved in one-third of patients, the Food and Drug Administration said. "The 95 percent retention...

2005-11-14 14:33:08

LOS ANGELES (Reuters) - Genentech Inc. and Biogen Idec Inc.'s cancer drug Rituxan improved symptoms of rheumatoid arthritis in patients not helped by drugs designed to block an inflammation-causing protein, researchers said on Sunday. Rituxan, currently sold as a treatment for non-Hodgkin's lymphoma, improved arthritis symptoms by at least 20 percent in 51 percent of patients who took the drug, compared with 18 percent of patients who took a placebo, according to results from the...

2005-10-19 07:19:29

CHICAGO (Reuters) - Genentech Inc. said on Tuesday early results from a mid-stage trial show that combining lung cancer drug Tarceva with Avastin works no better than Avastin alone in patients with advanced kidney cancer, sending shares of Tarceva partner OSI Pharmaceuticals Inc. down 7 percent. As a result, the world's No. 2 biotechnology company said it will not pursue further studies of the Avastin/Tarceva combination in kidney cancer but will continue to analyze the results of...

2005-07-20 10:47:03

WASHINGTON (Reuters) - Genentech Inc. and U.S. regulators have added a warning about the risk of a certain type of anemia with the biotech company's Raptiva drug for psoriasis, according to a letter made public on Wednesday. The company and the Food and Drug Administration also strengthened warnings about the risk of serious infections and decreased blood platelets that may be associated with Raptiva, said the letter to doctors dated Friday. Genentech shares were up 61 cents, or nearly 1...

2005-07-18 11:59:19

NEW YORK (Reuters) - Genentech Inc. on Monday said the average patient with age-related macular degeneration who received its experimental drug Lucentis could read an additional seven letters of a reading chart, compared with a vision loss of 10.5 letters among those who received sham injections. The favorable difference, amounting to about 17 letters, was seen in a one year-trial, whose results were presented by researchers at a medical meeting in Montreal. Genentech has said that U.S....

2004-11-29 15:00:00

SAN FRANCISCO -- Genentech Inc. said Monday its novel colon cancer-fighting drug Avastin helped some of the sickest patients stay alive two months longer than expected, giving the drug an additional boost on its way to blockbuster status. The South San Francisco-based biotechnology titan made the announcement ahead of a major conference for cancer researchers and doctors scheduled for January, when the company said it would release more detailed results from a large-scale human experiment...

2004-11-29 12:00:19

SOUTH SAN FRANCISCO, Calif. and BASEL, Switzerland, Nov. 29 /PRNewswire-FirstCall/ -- Genentech, Inc. and Roche (SWX Zurich) today announced that a randomized Phase III study of Avastin(TM) (bevacizumab) plus the FOLFOX4 chemotherapy regimen (oxaliplatin/5-FU/leucovorin), compared to FOLFOX4 alone, in second-line metastatic colorectal cancer patients achieved its primary endpoint of improving overall survival. Results from an interim analysis demonstrated that patients receiving Avastin...

Word of the Day
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'